Accuracy of the BRCAPRO Model Among Women With Bilateral Breast Cancer

被引:12
作者
Ready, Kaylene J. [1 ]
Vogel, Kristen J. [2 ]
Atchley, Deann P.
Broglio, Kristine R.
Solomon, Kimberly K.
Amos, Christopher
Lu, Karen H.
Hortobagyi, Gabriel N.
Arun, Banu
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77230 USA
[2] Evanston NW Healthcare Ctr Med Genet, Evanston, IL USA
关键词
BPCA1; gene; BPCA2; breast neoplasms; genetic models; CARRIER PROBABILITIES; GENETIC-HETEROGENEITY; SUSCEPTIBILITY GENES; MUTATIONS; FAMILIES;
D O I
10.1002/cncr.24102
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The likelihood of identifying a BPCA mutation was often calculated using the BRCAPRO model. A previous study suggested that this model may overestimate the chance of detecting a BPCA mutation among women diagnosed with bilateral breast cancer. Studies also suggested that few patients with bilateral breast cancer whose age at first diagnosis is >40 years were mutation carriers. The objectives of this study were to determine the accuracy of the BRCAPRO model among women with bilateral breast cancer and to determine whether their mutation status was dependent on their age at first diagnosis. METHODS: A retrospective chart review was performed. Women who were diagnosed with bilateral or unilateral breast cancer and who had undergone comprehensive BPCA1 and BPCA2 genetic testing at M. D. Anderson Cancer Center between 1997 and 2006 were included in the study. RESULTS: For individuals with pre-test carrier probabilities >31%, the proportion of positive tests was significantly lower than predicted by the BRCAPRO model (P <.05). In addition, the carrier rate of BPCA mutations was significantly higher (P = .002, Fisher exact test) in women with bilateral breast cancer whose age at first diagnosis was <= 40 years compared with those diagnosed >40 years. CONCLUSIONS: The BRCAPRO model was overestimating the relative contribution bilateral breast cancer had on the likelihood of detecting a BRCA1 or BPCA2 mutation. Bilateral breast cancer did not appear to be a good indicator of mutation status, particularly for women whose age at first diagnosis is >40 years. Cancer 2009;115:725-30. (C) 2009 American Cancer Society.
引用
收藏
页码:725 / 730
页数:6
相关论文
共 12 条
  • [1] Assessing BRCA carrier probabilities in extended families
    Barcenas, CH
    Hosain, GMM
    Arun, B
    Zong, JH
    Zhou, XJ
    Chen, JF
    Cortada, JM
    Mills, GB
    Tomlinson, GE
    Miller, AR
    Strong, LC
    Amos, CI
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) : 354 - 360
  • [2] BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes
    Berry, DA
    Iversen, ES
    Gudbjartsson, DF
    Hiller, EH
    Garber, JE
    Peshkin, BN
    Lerman, C
    Watson, P
    Lynch, HT
    Hilsenbeck, SG
    Rubinstein, WS
    Hughes, KS
    Parmigiani, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2701 - 2712
  • [3] Cancer risks in BRCA2 mutation carriers, 1999, J NATL CANC I, V91, P1310
  • [4] Characterization of BRCA1 and BRCA2 mutations in a large United States sample
    Chen, SN
    Iversen, ES
    Friebel, T
    Finkelstein, D
    Weber, BL
    Eisen, A
    Peterson, LE
    Schildkraut, JM
    Isaacs, C
    Peshkin, BN
    Corio, C
    Leondaridis, L
    Tomlinson, G
    Dutsm, D
    Kerber, R
    Amos, CI
    Strong, LC
    Berry, DA
    Euthus, DM
    Parmigiani, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 863 - 871
  • [5] BRCA1 mutations in southern England
    Eccles, DM
    Englefield, P
    Soulby, MA
    Campbell, IG
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (12) : 2199 - 2203
  • [6] Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
    Ford, D
    Easton, DF
    Stratton, M
    Narod, S
    Goldgar, D
    Devilee, P
    Bishop, DT
    Weber, B
    Lenoir, G
    Chang-Claude, J
    Sobol, H
    Teare, MD
    Struewing, J
    Arason, A
    Scherneck, S
    Peto, J
    Rebbeck, TR
    Tonin, P
    Neuhausen, S
    Barkardottir, R
    Eyfjord, J
    Lynch, H
    Ponder, BAJ
    Gayther, SA
    Birch, JM
    Lindblom, A
    Stoppa-Lyonnet, D
    Bignon, Y
    Borg, A
    Hamann, U
    Haites, N
    Scott, RJ
    Maugard, CM
    Vasen, H
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) : 676 - 689
  • [7] BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer
    Gershoni-Baruch, R
    Dagan, E
    Fried, G
    Kepten, I
    Robinson, E
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 1999, 7 (07) : 833 - 836
  • [8] Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
    King, MC
    Marks, JH
    Mandell, JB
    [J]. SCIENCE, 2003, 302 (5645) : 643 - 646
  • [9] Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations
    Marroni, F
    Aretini, P
    D'Andrea, E
    Caligo, MA
    Cortesi, L
    Viel, A
    Ricevuto, E
    Montagna, M
    Cipollini, G
    Ferrari, S
    Santarosa, M
    Bisegna, R
    Bailey-Wilson, JE
    Bevilacqua, G
    Parmigiani, G
    Presciuttini, S
    [J]. JOURNAL OF MEDICAL GENETICS, 2004, 41 (04) : 278 - 285
  • [10] Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Metcalfe, K
    Lynch, HT
    Chadirian, P
    Tung, N
    Olivotto, V
    Warner, E
    Olopade, OI
    Eisen, A
    Weber, B
    McLennan, J
    Sun, P
    Foulkes, WD
    Narod, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2328 - 2335